IPM Take
This is the kind of article IPM should publish because it shows seriousness. Radiopharmaceuticals are exciting, but excitement is not an implementation strategy. If a combination does not meet its endpoint, the answer is not spin. The answer is better patient selection, better trial design, and a refusal to let infrastructure-heavy treatments move into practice on hope.
Executive Summary
The randomized phase II RADICAL trial evaluated cabozantinib with or without radium-223 in metastatic renal cell carcinoma with at least one bone metastasis. The study was stopped for futility after a prespecified interim analysis. The addition of radium-223 did not improve symptomatic skeletal event-free survival. Median symptomatic skeletal event-free survival was 16.7 months with the combination versus 7.6 months with cabozantinib alone, with a subdistribution hazard ratio of 1.46 and 90% CI 0.86–2.51, meaning the primary endpoint was not met. Overall survival numerically favoured the combination, at 28.3 months versus 19.7 months, but this was hypothesis-generating. Grade 3 or higher adverse events occurred in 69.6% versus 75.5% of patients.
Why it matters
- Patients / advocates: Patients with bone metastases need evidence-backed options, not treatments added because the mechanism sounds logical.
- Clinicians: The trial challenges a plausible combination and protects practice from moving too fast.
- Hospitals / providers: Radiopharmaceutical delivery requires infrastructure; negative evidence matters before capacity is redirected.
- Payers / HTA bodies: Expensive, complex combination approaches need meaningful endpoint gains, not only biological rationale.
Oncology needs more negative trials that people actually read.
RADICAL tested a reasonable idea. Bone metastases in renal cell carcinoma are painful, dangerous and clinically consequential. Cabozantinib has activity in RCC. Radium-223 targets bone. The combination made biological sense.
Then the trial asked the only question that matters: does it improve outcomes?
It did not meet its primary endpoint.
That does not make the study a waste. It makes it useful. In a field increasingly crowded with combinations, biomarkers, radiopharmaceuticals and mechanistic logic, the most valuable word may sometimes be no.
The result should also slow down the lazy part of the radiopharmaceutical conversation. These therapies are not just drugs. They require nuclear medicine capacity, radiation safety, scheduling, trained teams, reimbursement, isotope logistics and patient selection. When systems invest around them, the evidence bar has to be high.
There is a nuance. Overall survival numerically favoured the combination, but the trial was not positive on its primary skeletal endpoint, and the OS signal remains hypothesis-generating. That is exactly the distinction policy needs to respect. A secondary signal can guide research. It should not become routine practice by press-release momentum.
Patients with metastatic RCC and bone disease need better care. They need pain control, fracture prevention, systemic therapy, local interventions, imaging, supportive care and trials that ask hard questions. They do not need every plausible combination added to an already heavy pathway.
RADICAL is a necessary no. And necessary noes are part of good cancer policy.
